Erelzi® (etanercept-szzs)

aBL 761042

Erelzi® (etanercept-szzs)

aBL 761042

U.S. License Holder:

Sandoz Inc.

Date of License:

August-30-2016

Last Update:

January-08-2021

approved_indications FDA-Approved Indications

ERELZI (etanercept-szzs) is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

Rheumatoid Arthritis (RA);

Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older;

Ankylosing Spondylitis (AS);

Plaque Psoriasis (PsO) in adults.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Erelzi (Sandoz) (April-2017)

Biosimilars Approved In The E.U.

Erelzi (Sandoz) (June-2017)

approved_indications U.S. Patent Litigations

PACER

Case No(s):

2:16-cv-01118 (D.N.J.)

U.S. Patent Nos.
7,915,225 (Soluble Tumor Necrosis Factor Receptor Treatment of Medical Disorders) 8,063,182 (Human TNF Receptor Fusion Protein) 8,119,605 (Soluble Tumor Necrosis Factor Receptor Treatment of Medical Disorders) 8,163,522 (Human TNF Receptor) 8,722,631 (Soluble Tumor Necrosis Factor Receptor Treatment of Medical Disorders)

Plaintiffs
Amgen Manufacturing, Ltd.; Hoffmann-La Roche Inc.; Immunex Corp.

Defendants
Sandoz GmbH; Sandoz, Inc.; Sandoz International GmbH

Federal Circuit Appeal(s)
20-1037

Status
District Court Determination that Patents Not Invalid, Stipulation of Infringement; Permanent Injunction Issued; Federal Circuit Affirmed, Petition for Panel Rehearing and En Banc Rehearing Denied

BPCIA
Y

3:13-cv-02904 (N.D. Cal.)

U.S. Patent Nos.
8,063,182 (Human TNF Receptor Fusion Protein) 8,163,522 (Human TNF Receptor)

Plaintiffs
Sandoz, Inc.

Defendants
Amgen Inc.; Hoffmann-La Roche, Inc.

Federal Circuit Appeal(s)
14-1693

Status
Complaint Dismissed for Lack of Subject Matter Jurisdiction; Federal Circuit Affirmed

BPCIA
N

related articles Related News Articles

Spotlight On: Biosimilar Litigations April Breyer Menon; Ha Kung Wong December 31, 2020
Spotlight On: Enbrel® (etanercept) / Erelzi® (etanercept-szzs) / Eticovo® (etanercept-ykro) April Breyer Menon; Joseph K. Yarsky; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 31, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong December 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong November 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong October 8, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong September 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong August 10, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong July 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – May 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong June 8, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2020 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong May 6, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – March 2020 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong April 8, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2020 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong March 12, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – January 2020 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong February 6, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong January 7, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 9, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D.; Ha Kung Wong November 11, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. October 8, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – August 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. September 9, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. August 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 9, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – May 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. June 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. May 7, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – March 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. April 5, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – January 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. February 11, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 9, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 26, 2017

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha